Juha Punnonen

Juha Punnonen currently serves as Chief Development Officer at Hinge Bio since April 2023 and has been a Life Sciences Advisor for Biotechnology since July 2022. Prior experience includes roles as Senior Vice President & Head of Oncology at Ascendis Pharma from September 2018 to June 2022, and Executive Director of Cancer Immunotherapy at Merck from April 2015 to August 2018. Punnonen co-founded STATegics, Inc. where the position of CEO was held from May 2007 to April 2015. Earlier roles include Vice President of R&D at Maxygen, Scientist at DNAX/Schering-Plough Biopharma, Acting Assistant Professor at the University of Turku, and a Post-doctoral fellow at DNAX Research Institute/Schering-Plough. Punnonen began a medical career in regional hospitals and healthcare centers as a physician from 1989 to 1991. Educational qualifications include an MD and PhD from the University of Turku in Finland.